<!DOCTYPE html><html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"><meta name="format-detection" content="telephone=no"><meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no"><link rel="stylesheet" href="css/main.min.css"><script src="js/all.min.js"></script><script type="text/javascript">var slideNumber = 11</script></head><body class="s11"><div class="content-wrap"><nav><div onclick="iRep.go(1)" class="home-button"></div><ul><li onclick="iRep.go(3)" class="real-world-evidence"><span>REAL WORLD</span></li><li onclick="iRep.go(4)" class="evidence active"><span>EVIDENCE</span></li><li onclick="iRep.go(12)" class="reversal"><span>REVERSAL</span></li><li onclick="iRep.go(14)" class="take-action"><span>COST</span></li><li onclick="iRep.goToolbox()" class="toolbox"><span>TOOLBOX</span></li><li onclick="iRep.go(16)" class="pi"><span>PI</span></li></ul></nav><div class="page-nav"><div onclick="iRep.go(12)" class="page-next"></div><div onclick="iRep.go(9)" class="page-prev"></div></div><article><div class="panel1"><h3>Rivaroxaban 15mg and 20mg o.d.: bleeding outcomes<sup>1,2</sup></h3><div class="labels"><div onclick="iRep.go(9)" class="label"><div class="text">PRADAXA<sup>®</sup> 150mg</div></div><div onclick="iRep.go(10)" class="label"><div class="text">APIXABAN <br/>2.5 & 5mg</div></div><div class="label"><div class="text">RIVAROXABAN <br/> 15 & 20mg</div></div></div><div class="down-bar"></div><div class="hr-text">HR: 1.66 (1.34-2.05)</div><div class="graph"><div class="chart"><div class="title">Rivaroxaban 15mg and 20mg b.d.<sup>1,2</sup></div><div class="bars"><span>INTRA-CRANIAL</span><div class="bar bar1"><div class="text">0.20% ARR<br/>33% RRR<br><span>(p=0.02)</span></div></div></div><div class="bars"><span>MAJOR</span><div class="bar bar2"><div class="text">0.20% ARI<br/>4% RRI<br/><span>(p=ns)</span></div></div></div><div class="bars"><span>MAJOR GI</span><div class="bar last bar3"><div class="text">0.76% ARI<br/>66% RRI<br/><span>(p<0.0001)</span></div></div></div></div><div class="chart2"><div class="title">Pradaxa<sup>®</sup> 150mg b.d.<sup>4-6</sup></div><div class="bars"><span>INTRA-CRANIAL</span><div class="bar bar1"><div class="text">0.44% ARR<br/>59% RRR<br/><span>(p<0.001)</span></div></div></div><div class="bars"><span>MAJOR</span><div class="bar bar2"><div class="text">0.21% ARR<br/>6% RRR<br/><span>(p=ns)</span></div></div></div><div class="bars"><span>MAJOR GI</span><div class="bar last bar3"><div class="text">0.49% ARI<br/>48% RRI<br/><span>(p=0.001)</span></div></div></div></div><div class="over-bar"><p>W</p></div><div class="left"></div><div class="note">Please note that these data are not from a head-to-head trial</div></div></div></article><div class="overlay"></div><div class="sidebar"><ul><li class="brain-tab tab"></li><li class="references-tab tab"></li></ul><div class="panel"><div class="close-button"></div><div class="content references"><div class="text"><b>References: 1.</b> Patel MR,<em> et al. N Engl J Med</em> 2011;365:883–891.<b> 2.</b> Sherwood MV,<em> et al. J Am Coll Cardiol</em> 2015;66(21):2271–2281.<b> 3.</b> Mahaffey KW and Fox KAA. <br/> Presented at AHA scientific sessions 2010; abstract 21839.<b> 4.</b> Connolly SJ,<em> et al. N Engl J Med</em> 2009;361:1139–1151.<b> 5.</b> Connolly SJ,<em> et al. N Engl J Med <br/></em> 2010;363:1875–1876.<b> 6.</b> Connolly SJ,<em> et al. N Engl J Med</em> 2014;371:1464–1465.<b> 7.</b> Boehringer Ingelheim. Pradaxa<sup>®</sup> 150mg hard capsules Summary of Product <br/> Characteristics.</div></div><div class="content brain"><h3 class="title-popup">Rivaroxaban 15mg and 20mg o.d.: stroke outcomes<sup>1,3*</sup></h3><div class="down-bar"></div><div class="graph"><div class="chart"><div class="title-graph">Rivaroxaban 15mg and 20mg b.d.<sup>1,3</sup></div><div class="bars"><div class="title1">ISCHAEMIC</div><div class="bar bar1"><div class="text">0.02% ARR<br/>1% RRR</br><span>(p=ns)</span></div></div></div><div class="bars"><div class="title1">HAEMORR-<br/>HAGIC</div><div class="bar bar2"><div class="text">0.18% ARR<br/>42% RRR<br/><span>(p=0.01)</span></div></div></div><div class="bars"><div class="title1">STROKE/</br>SYSTEMIC<br/>EMBOLISM</div><div class="bar last bar3"><div class="text">0.30% ARR<br/>12% RRR<br/><span>(p=ns)</span></div></div></div></div><div class="chart2"><div class="title-graph">Pradaxa<sup>®</sup> 150mg b.d.<sup>4-7</sup></div><div class="bars"><div class="title1">ISCHAEMIC</div><div class="bar bar1"><div class="text">0.28% ARR<br/>24% RRR<br/><span>(p=0.035)</span></div></div></div><div class="bars"><div class="title1">HAEMORR-<br/>HAGIC</div><div class="bar bar2"><div class="text">0.28% ARR<br/>74% RRR<br/><span>(p<0.001)</span></div></div></div><div class="bars"><div class="title1">STROKE/</br>SYSTEMIC<br/>EMBOLISM</div><div class="bar last bar3"><div class="text">0.60% ARR<br/>35% RRR<br/><span>(p<0.001)</span></div></div></div></div><div class="over-bar"><p>W</p></div><div class="left"></div><div class="note">Please note that these data are not from a head-to-head trial</div><div class="note2">* Intention-to-treat population</div></div></div></div></div></div></body></html>